Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: An exploratory study

Neurological Research

Volumn 34, Issue 1, 2012, Pages 52-58

  Blinkenberg, Morten ^a   Mathiesen, Henrik K ^a   Tscherning, Thomas ^a   Jønsson, Agnete ^a   Svarer, Claus ^a   Holm, Søren ^a   Sellebjerg, Finn ^a   Paulson, Olaf B ^a   Hanson, Lars G ^a,b   Sorensen, Per S ^a  

^a Mental Health Services CPH   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Cerebral metabolism; Cognitive dysfunction; MRI; MRS; Multiple sclerosis; PET

Indexed keywords

CREATINE; FLUORODEOXYGLUCOSE F 18; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN METABOLISM; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EXPLORATORY RESEARCH; FEMALE; HIPPOCAMPUS; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PUTAMEN; REGRESSION ANALYSIS;

ADULT; ASPARTIC ACID; BRAIN; CEREBRAL CORTEX; COGNITION DISORDERS; CREATINE; FEMALE; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POSITRON-EMISSION TOMOGRAPHY; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 84555219841     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132811Y.0000000059     Document Type: Article

References (31)

1. Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science 1988;241:462-4.
2. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD. Nacetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002;51:51-8.
3. Blinkenberg M, Rune K, Jensen CV, Ravnborg M, Kyllingsbaek S, Holm S, et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology 2000;54:558-64.
4. Paulesu E, Perani D, Fazio F, Comi G, Pozzilli C, Martinelli V, et al. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. Neuroimage 1996;4:87-96.
5. Sun X, Tanaka M, Kondo S, Okamoto K, Hirai S. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med 1998;12:89-94.
6. Mathiesen HK, Jonsson A, Tscherning T, Hanson LG, Andresen J, Blinkenberg M, et al. Correlation of global Nacetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol 2006;63:533-6.
7. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994;35:1398-406.
8. Patlak CS, Blasberg RG. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-90.
9. Hasselbalch SG, Madsen PL, Knudsen GM, Holm S, Paulson OB. Calculation of the FDG lumped constant by simultaneous measurements of global glucose and FDG metabolism in humans. J Cereb Blood Flow Metab 1998;18:154-60.
10. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 2005;24:969-79.
11. Gasperini C, Paolillo A, Rovaris M, Yousry TA, Capra R, Bastianello S, et al. A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imag 2000;18:761-3.
12. Mathiesen HK, Tscherning T, Sorensen PS, Larsson HB, Rostrup E, Paulson OB, et al. Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. Magn Reson Med 2005;53:750-9.
13. Ashburner J, Friston KJ. Rigid body registration. In: Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Price CJ, Zeki S, Ashburner J, Penny W, editors. Human brain function. 2nd ed. San Diego, CA: Academic Press; 2003, 2-24.
14. Willendrup P, Pinborg LH, Hasselbalch SG, Adams KH, Stahr K, Knudsen GM, et al. Assessment of the precision in coregistration of structural MR images and PET images with localized binding. Int Cong Ser 2004;1265:275-80.
15. Jonsson A, Andresen J, Storr L, Tscherning T, Soelberg Sorensen P, Ravnborg M. Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study. J Neurol Sci 2006;245:77-85.
16. Blinkenberg M, Rune K, Jonsson A, Holm S, Jensen CV, Paulson OB, et al. Cerebral metabolism in a case of multiple sclerosis with acute mental disorder. Acta Neurol Scand 1996;94:310-3.
17. Derache N, Marie RM, Constans JM, Defer GL. Reduced thalamic and cerebellar rest metabolism in relapsing-remitting multiple sclerosis, a positron emission tomography study: correlations to lesion load. J Neurol Sci 2006;245:103-9.
18. Bakshi R, Miletich RS, Kinkel PR, Emmet ML, Kinkel WR. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 1998;8:228-34.
19. Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005;15:10S-21S.
20. Adalsteinsson E, Langer-Gould A, Homer RJ, Rao A, Sullivan EV, Lima CA, et al. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003;24:1941-5.
21. Sijens PE, Mostert JP, Oudkerk M, De Keyser J. (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings. Eur Radiol 2006;16:489-95.
22. Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsingremitting multiple sclerosis. Brain 2002;125:2342-52.
23. Tiberio M, Chard DT, Altmann DR, Davies G, Griffin CM, McLean MA, et al. Metabolite changes in early relapsingremitting multiple sclerosis. A two year follow-up study. J Neurol 2006;253:224-30.
24. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121(Pt 8):1469-77.
25. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-9.
26. Kapeller P, McLean MA, Griffin CM, Chard D, Parker GJ, Barker GJ, et al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 2001;248:131-8.
27. He J, Inglese M, Li BS, Babb JS, Grossman RI, Gonen O. Relapsing-remitting multiple sclerosis: metabolic abnormality in nonenhancing lesions and normal-appearing white matter at MR imaging: initial experience. Radiology 2005;234:211-7.
28. Wattjes MP, Harzheim M, Lutterbey GG, Bogdanow M, Schild HH, Traber F. High field MR imaging and 1H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol 2008;255:56-63.
29. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65-70.
30. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, Ammann W, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48:1566-71.
31. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-51.